Axonal transection in the lesions of multiple sclerosis

New England Journal of Medicine

Volumn 338, Issue 5, 1998, Pages 278-285

  Trapp, Bruce D ^a   Peterson, John ^a   Ransohoff, Richard M ^a   Rudick, Richard ^a   Mörk, Sverre ^b   Bö, Lars ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BRAIN TISSUE; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DEMYELINATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MULTIPLE SCLEROSIS; NERVE FIBER TRANSECTION; PRIORITY JOURNAL; WHITE MATTER;

ADOLESCENT; ADULT; AXONS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY, CONFOCAL; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN SHEATH;

EID: 0032576752     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199801293380502     Document Type: Article

References (52)

1. Weinshenker BG. Epidemiology of multiple sclerosis. Neurol Clin 1996;14:291-308.
2. Sawcer S, Jones HB, Feakes R, et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat Genet 1996;13:464-8.
3. Haines JL, Ter-Minassian M, Bazyk A, et al. A complete genomic screen for multiple sclerosis underscores a role tor the major histocompatibility complex: the Multiple Sclerosis Genetics Group. Nat Genet 1996;13:469-71.
4. Ebers GC, Kukay K, Bulman DE, et al. A full genome search in multiple sclerosis. Nat Genet 1996;13:472-6.
5. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32:758-66.
6. Rudick RA, Cookfair D, Ransohoff R, et al. Cerebrospinal fluid abnormalities in a phase III trial interferon beta-1a (Avonex) for relapsing multiple sclerosis. Ann Neurol 1996;40:516. abstract.
7. Bornstein MB, Crain SM. Functional studies of cultured human brain tissues as related to "demyelinative disorders." Science 1965;148:1242-4.
8. Prineas JW, Graham JS. Multiple sclerosis: capping of surface immunoglobulin G on macrophages engaged in myelin breakdown. Ann Neurol 1981;10:149-58.
9. Prineas JW, Kwon EE, Cho ES, Sharer LR. Continual breakdown and regeneration of myelin in progressive multiple sclerosis plaques. Ann N Y Acad Sci 1984;436:11-32.
10. Milligan NM, Newcombe R, Compston DAS. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis. I. Clinical effects. J Neurol Neurosurg Psychiatry 1987;50:511-6.
11. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133-46.
12. Losseff NA, Webb SL, O'Riordan JI, et al. Spinal cord atrophy and disability in multiple sclerosis: a new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996;119:701-8.
13. Davie CA, Barker GJ, Webb S, et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 1995;118:1583-92.
14. Losseff NA, Wang L, Lai HM, et al. Progressive cerebral atrophy in multiple sclerosis: a serial MRI study. Brain 1996;119:2009-19.
15. Arnold DL, Riess GT, Matthews PM, et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol 1994,36:76-82.
16. Davie CA, Hawkins CP, Barker GJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994;117:49-58.
17. De Stefano N, Matthews PM, Antel JP, Preul M, Francis G, Arnold DL. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 1995;38:901-9.
18. Matthews PM, Pioro E, Narayanan S, et al. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain 1996;119:715-22.
19. McDonald WI. Rachelle Fishman-Matthew Moore Lecture: the pathological and clinical dynamics of multiple sclerosis. J Neuroparhol Exp Neurol 1994;53:338-43.
20. Narayanan S, Fu L, Pioro E, et al. Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol 1997;41:385-91.
21. Charcot M. Histologie de la sclerose en plaques. Gaz Hosp 1868;141: 554-5, 557-8.
22. Raine CS, Cross AH. Axonal dystrophy as a consequence of long-term demyelination. Lab Invest 1989;60:714-25.
23. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997;120:393-9.
24. Bö L, Mörk S, Kong PA, Nyland H, Pardo CA, Trapp BD. Detection of MHC class II-antigens on macrophages and microglia, but not on astrocytes and endothelia in active multiple sclerosis lesions. J Neuroimmunol 1994;51:135-46.
25. Trapp BD, Nishiyama A, Cheng D, Macklin W. Differentiation and death of premyelinating oligodendrocytes in developing rodent brain. J Cell Biol 1997;137:459-68.
26. Norton WT, Poduslo SE. Myelination in rat brain: method of myelin isolation. J Neurochem 1973;21:749-57.
27. Prineas JW. The neuropathology of multiple sclerosis: In: Koetsier JC, ed. Demyelinating diseases. Vol. 47 of Handbook of clinical neurology. Amsterdam: Elsevier Science, 1985:213-57
28. Bö L, Peterson JW, Mörk S, et al. Distribution of immunoglobulin superfamily members ICAM-1, -2, -3, and the β2 integrin LFA-1 in multiple sclerosis lesions. J Neuropathol Exp Neurol 1996;55:1060-72.
29. Sternberger LA, Sternberger NH. Monoclonal antibodies distinguish phosphorylated and nonphosphorylated forms of neurofilaments in situ. Proc Natl Acad Sci U S A 1983;80:6126-30.
30. Lee VM-Y, Carden MJ, Trojanowski JQ. Novel monoclonal antibodies provide evidence for the in situ existence of a nonphosphorylated form of the largest neurofilament subunit. J Neurosci 1986;6:850-8.
31. Lee VM, Garden MJ, Schlaepfer WW, Trojanowski JQ. Monoclonal antibodies distinguish several differentially phosphorylated states of the two largest rat neurofilament subunits (NF-H and NF-M) and demonstrate their existence in the normal nervous system of adult rats. J Neurosci 1987; 7:3474-88.
32. Cochran E, Bacci B, Chen Y, Patton A, Gambetti P, Autilio-Gambetti L. Amyloid precursor protein and ubiquitin immunoreactivity in dystrophic axons is not unique to Alzheimer's disease. Am J Pathol 1991; 139:485-9.
33. Gentleman SM, Nash MJ, Sweeting CJ, Graham DI, Roberts GW. Beta-amyloid precursor protein (beta APP) as a marker for axonal injury after head injury. Neurosci Lett 1993;160:139-44.
34. Ohgami T, Kitamoto T, Tateishi J. Alzheimer's amyloid precursor protein accumulates within axonal swellings in human brain lesions. Neurosci Lett 1992;136:75-8.
35. Sherriff FE, Bridges LR, Gentleman SM, Sivaloganathan S, Wilson S. Markers of axonal injury in post mortem human brain. Acta Neuropathol (Berl) 1994;88:433-9.
36. IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Interferon beta-lb in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-85.
37. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94.
38. Selmaj K, Raine CS, Cannella B, Brosnan CF. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 1991;87:949-54.
39. Bö L, Dawson TM, Wesselingh S, et al. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol 1994;36:778-86.
40. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis: principles, problems and perspectives. Brain 1997;120:865-916.
41. Windebank AJ, Wood P, Bunge RP, Dyck PJ. Myelination determines the caliber of dorsal root ganglion neurons in culture. J Neurosci 1985;5: 1563-9.
42. Sanchez I, Hassinger L, Paskevich PA, Shine HD, Nixon RA. Oligodendroglia regulate the regional expansion of axon caliber and local accumulation of neurofilaments during development independently of myelin formation. J Neurosci 1996;16:5095-105.
43. Fruttiger M, Montag D, Schachner M, Martini R. Crucial role for the myelin-associated glycoprotein in the maintenance of axon-myelin integrity. Eur J Neurosci 1995;7:511-5.
44. Trapp BD, Andrews SB, Cootauco C, Quarles RH. The myelin-associated glycoprotein is enriched in multivesicular bodies and periaxonal membranes of actively myelinating oligodendrocytes. J Cell Biol 1989;109: 2417-26.
45. Hoffman PN, Lasek RJ. The slow component of axonal transport: identification of major structural polypeptides of the axon and their generality among mammalian neurons. J Cell Biol 1975;66:351-66.
46. Hirokawa N, Glicksman MA, Willard MB. Organization of mammalian neurofilament polypeptides within the neuronal cytoskeleton. J Cell Biol 1984;98:1523-36.
47. Nakagawa T, Chen J, Zhang Z, Kanai Y, Hirokawa N. Two distinct functions of the carboxyl-terminal tail domain of NF-M upon neurofilament assembly: cross-bridge formation and longitudinal elongation of filaments. J Cell Biol 1995;129:411-29.
48. Arbuthnott ER, Boyd IA, Kalu KU. Ultrastructural dimensions of myelinated peripheral nerve fibers in the cat and their relation to conduction velocity. J Physiol (Lond) 1980;308:125-57.
49. deWaegh SM, Lee VM-Y, Brady ST. Local modulation of neurofilament phosphorylation, axonal caliber, and slow axonal transport by myelinating Schwann cells. Cell 1992;68:451-63.
50. Hsieh S-T, Crawford TO, Bouldin TW, Griffin JW. Influence of demyelination and remyelination on axonal organization. Brain Pathol 1993; 3:307.
51. De Stefano N, Matthews PM, Arnold DL. Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 1995;34:721-7.
52. Mehta V, Namboodiri MAA. N-acetylaspartate as an acetyl source in the nervous system. Brain Res Mol Brain Res 1995;31:151-7.